Antibodies News and Research

RSS
Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

UC San Diego receives $33 million from NIH for five COVID-19 diagnostic projects

UC San Diego receives $33 million from NIH for five COVID-19 diagnostic projects

Research shows effective strategy to target the SARS-CoV-2 spike protein

Research shows effective strategy to target the SARS-CoV-2 spike protein

Research shows how antibodies attach to and block Zika virus

Research shows how antibodies attach to and block Zika virus

Study reports lasting immune response in convalescent COVID-19 patients

Study reports lasting immune response in convalescent COVID-19 patients

Anti-phospholipid antibodies in severely ill patients not distinctive to COVID-19, says study

Anti-phospholipid antibodies in severely ill patients not distinctive to COVID-19, says study

Study of children hospitalized with COVID-19 shows 2% mortality

Study of children hospitalized with COVID-19 shows 2% mortality

'Miracle poison' can target a variety of different proteins

'Miracle poison' can target a variety of different proteins

Lab study of South African SARS-CoV-2 variant and Moderna vaccine: reduced neutralization, but still protective

Lab study of South African SARS-CoV-2 variant and Moderna vaccine: reduced neutralization, but still protective

Full characterization of mammalian-produced SARS-CoV-2 receptor binding domains

Full characterization of mammalian-produced SARS-CoV-2 receptor binding domains

Study shows antibody responses persisting 10 months after SARS-CoV-2 infection

Study shows antibody responses persisting 10 months after SARS-CoV-2 infection

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

GW team to play a role in Sanofi COVID-19 vaccine clinical trial

GW team to play a role in Sanofi COVID-19 vaccine clinical trial

Basigin does not facilitate SARS-CoV-2 entry, say researchers

Basigin does not facilitate SARS-CoV-2 entry, say researchers

UK and South African SARS-CoV-2 variants show higher binding affinity to host cell receptor

UK and South African SARS-CoV-2 variants show higher binding affinity to host cell receptor

Study reveals how cancer cells escape death by lymphocytes

Study reveals how cancer cells escape death by lymphocytes

Long-lasting B cells do not recognize emerging SARS-CoV-2 variants, shows study

Long-lasting B cells do not recognize emerging SARS-CoV-2 variants, shows study

COVID-19 may alter host proteins to cause autoimmunity

COVID-19 may alter host proteins to cause autoimmunity

SARS-CoV-2 variants emerge during humoral immunity phase of acute COVID-19

SARS-CoV-2 variants emerge during humoral immunity phase of acute COVID-19